Fecal microbiome alterations in treatment-naive de novo Parkinson's diseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the fecal microbiome composition of treatment-naive, newly diagnosed Parkinson's disease (PD) patients using 16S sequencing. Earlier PD microbiome research could not rule out confounding effects from dopaminergic medication or long disease duration, since almost all prior participants were already medicated and studied years after diagnosis. Here, investigators assessed gut microbiota alterations at the time of diagnosis, before any PD medication was started, while accounting for potential confounders such as technical batches, diet, and constipation.
Who was studied?
The study included two large independent case-control cohorts. The first comprised 136 treatment-naive de novo PD subjects and 85 healthy controls, and the second comprised 56 PD subjects and 87 healthy controls. All PD participants were newly diagnosed and had not yet started dopaminergic medication, distinguishing this population from those in most prior PD microbiome studies.
What were the most important findings?
Overall gut microbiome composition differed between PD subjects and healthy controls in both cohorts, showing that gut microbiome alterations are already present at the time of PD diagnosis, independent of dopaminergic medication exposure. No single differentially abundant taxon was replicated across both cohorts, indicating some inconsistency at the individual-taxon level. However, multiple short chain fatty acid (SCFA) producing taxa were decreased in PD in both cohorts, with several taxa belonging to the family Lachnospiraceae reduced in abundance.
What are the greatest implications of this study?
By studying treatment-naive de novo patients, this work shows that gut microbiome alterations in PD are not simply a consequence of dopaminergic medication or prolonged disease duration, but are present from diagnosis onward. The consistent decrease in SCFA-producing and Lachnospiraceae taxa across two independent cohorts points to disrupted short chain fatty acid production as an early and reproducible feature of PD. These findings support continued investigation into gut microbiome changes, particularly SCFA metabolism, as a potential early contributor to PD pathogenesis rather than a downstream effect of treatment.